Hepatitis B immunoglobulin is an important drug to prevent the recurrence of hepatitis B after liver transplantation for hepatitis B-related liver disease. Now there is a shortage of drugs all over the country, we at the Liver Transplantation Center of Zhejiang Medical College put forward several measures to deal with this: 1. For liver transplantation year more than 1 year, immunosuppression is not much, you can consider active immunization, such as “An in time” hepatitis B vaccination, once a month, adhere to about half a year, the efficiency of about 40%, about 10% of liver friends can be out of the combination of lamivudine and hepatitis B immunoglobulin treatment, the establishment of Active immunity. The vaccine can be bought at local disease control centers. 3. If active immunization does not produce a response, you can add one adefovir daily (or even switch to entecavir). The dual drug barrier against hepatitis B relapse has been reported in the latest international academic journals to show comparable effectiveness to lamivudine combined with hepatitis B immunoglobulin in most foreign liver patients. However, the economics of efficacy and side effects of the drug need to be considered and it is recommended that your primary care physician adjust the medication and not make the decision on his or her own.